Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617331 · ClinicalTrials.gov registry record · Phase 2
H9 Priming Study in Healthy Adults
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT00617331 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 121 participants.
The verdict
NCT00617331, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether prior exposure to A/H2N2 viruses is associated with better antibody (part of the immune system that fights infection) responses after vaccination with an A/H9N2 flu vaccine. The study will evaluate how much antibody is made to the influenza virus after H9N2 flu vaccination and how the body reacts to different strengths of the H9N2 flu vaccine. This information may guide vaccine development for this virus as well as other bird flu viruses that have infected humans. Study participants will include 120 healthy subjects, age 18-38 or 44-59 years. Two different dosages of vaccine will be given in the muscle of the upper arm about 1 month apart. The assignment of vaccines to participants is governed by chance. Study procedures may include medical history, physical exam, and blood samples. Study participation duration is about 7 months.
Interventions
- BIOLOGICAL Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00617331
The ClinicalTrials.gov registry entry for NCT00617331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine is the first listed.
NCT00617331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00617331 about?
NCT00617331 is a clinical study titled "H9 Priming Study in Healthy Adults". The purpose of this research study is to determine whether prior exposure to A/H2N2 viruses is associated with better antibody (part of the immune system that fights infection) responses after vaccination with an A/H9N2 flu vaccine. The study will evaluate how much antibody is made to the influenza ...
What is the current status of trial NCT00617331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2008-02. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00617331?
The interventions under investigation include: Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00617331?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.